KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Depreciation and Depletion (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Depreciation and Depletion for 8 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 7.16% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Dec 2025, down 8.28% year-over-year, with the annual reading at $16.1 million for FY2025, 8.28% down from the prior year.
  • Depreciation and Depletion hit $3.7 million in Q4 2025 for Adaptive Biotechnologies, down from $4.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $5.3 million in Q3 2023 to a low of $2.3 million in Q1 2021.
  • Historically, Depreciation and Depletion has averaged $4.3 million across 5 years, with a median of $4.5 million in 2021.
  • Biggest five-year swings in Depreciation and Depletion: soared 129.73% in 2021 and later decreased 21.97% in 2024.
  • Year by year, Depreciation and Depletion stood at $4.4 million in 2021, then rose by 9.41% to $4.8 million in 2022, then grew by 1.96% to $4.9 million in 2023, then decreased by 18.47% to $4.0 million in 2024, then dropped by 7.16% to $3.7 million in 2025.
  • Business Quant data shows Depreciation and Depletion for ADPT at $3.7 million in Q4 2025, $4.0 million in Q3 2025, and $4.1 million in Q2 2025.